Phase 2B/3 ANAVEX(R)2-73 (Blarcamesine) Study Meets Primary and Key Secondary Endpoints

(24/7 MARKET NEWS) – (24/7 MARKET NEWS) – Anavex Life Sciences Corp. (Nasdaq: AVXL)announced, last night, positive topline results from its Phase 2b/3 ANAVEX(R)2-73-AD-004 clinical trial of oral ANAVEX(R)2-73 (blarcamesine) for the treatment of mild cognitive impairment (MCI) due to Alzheimer’s disease (AD) and mild AD (collectively known as early AD). The Company plans to meet with regulatory authorities to determine the next steps.

Anavex is trading at $9.50, up $0.63 (+7.10%), on nearly 500 thousand shares.

Its 52-week range is $7.13 to 20.24. Interesting chart that looks like it could fill in the gap to $11 and, if it does so on strong volume the next inflection point is at $12.60.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist